top of page
Pink Sugar

ACTIVITIES to thank all our supporters

And do our little things to support them back

Standing up for children with cancer

Publications

https://orcid.org/0000-0003-1214-9665

Selected Peer Reviewed Publications

  1. Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts. A Shea, Y Eyal-Lubling, D Guerrero-Romero, et al. Bruna A. bioRxiv, 2023

  2. MiR‐182‐3p targets TRF2 and impairs tumor growth of triple‐negative breast cancer. Dinami R, Pompili L, Petti E, Porru M, D'Angelo C, Di Vito S, Rizzo A, Campani V, De Rosa G, Bruna A, Serra V, Mano M, Giacca M, Leonetti C, Ciliberto G, Tarsounas M, Stoppacciaro A, Schoeftner S, Biroccio A. EMBO Mol Med. 2023 Jan 11;15(1):e16033. doi: 10.15252/emmm.202216033. Epub 2022 Nov 25.PMID: 36426578

  3. Wnt Signaling in the Breast: From Development to Disease. Abreu de Oliveira WA, El Laithy Y, Bruna A, Annibali D, Lluis F. Front Cell Dev Biol. 2022 May 18;10:884467.

  4. Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours.  roelly FJ, Porru M, Zimmer J, Benainous H, De Visser Y, Kosova AA, Di Vito S, Serra V, Ryan A, Leonetti C, Bruna A, Biroccio A, Tarsounas M.EMBO Mol Med. 2022 Mar 7;14(3):e14501. doi:  0.15252/emmm.202114501. Epub 2022 Feb 2.PMID: 35107878

  5. Predicting Cancer Drug Response In Vivo by Learning an Optimal Feature Selection of Tumour Molecular Profiles. Nguyen LC, Naulaerts S, Bruna A, Ghislat G, Ballester PJ.Biomedicines. 2021 Sep 26;9(10):1319. doi: 10.3390/biomedicines9101319.PMID: 34680436

  6. The Promise of Patient-Derived Preclinical Models to Accelerate the Implementation of Personalised Medicine for Children with Neuroblastoma. Tucker ER, George S, Angelini P, Bruna A, Chesler L.J PersMed. 2021 Mar30;11(4):248. doi: 10.3390/jpm11040248.PMID: 33808071

  7. DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation Batra RN, Lifshitz A, Vidakovic AT, Chin SF, Sati-Batra A, Sammut SJ, Provenzano E, Ali HR, Dariush A, Bruna A, Murphy L, Purushotham A, Ellis I, Green A, Garrett-Bakelman FE, Mason C, Melnick A, Aparicio SAJR, Rueda OM, Tanay A, Caldas C.. Nat Commun. 2021 Sep 13;12(1):5406.

  8. Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response.Georgopoulou D, Callari M, Rueda OM, Shea A, Martin A, Giovannetti A, Qosaj F, Dariush A, Chin SF, CarnevalliLS, Provenzano E, Greenwood W, Lerda G, Esmaeilishirazifard E, O'Reilly M, Serra V, Bressan D; IMAXT Consortium, Mills GB, Ali HR, Cosulich SS, Hannon GJ, Bruna A, Caldas C.Nat Commun. 2021 Mar 31;12(1):1998. doi: 10.1038/s41467-021-22303-z.PMID: 33790302 (Co-last)

  9. Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER+ Breast Cancer. Ros S, Wright AJ, D'Santos P, Hu DE, Hesketh RL, Lubling Y, Georgopoulou D, Lerda G, Couturier DL, Razavi P, Pelossof R, Batra AS, Mannion E, Lewis DY, Martin A, Baird RD, Oliveira M, de Boo LW, Linn SC, Scaltriti M, Rueda OM, Bruna A, Caldas C, Brindle KM.Cancer Cell. 2020 Oct 12;38(4):516-533.e9. doi: 10.1016/j.ccell.2020.08.016. Epub 2020 Sep 24.PMID:  2976773

  10. Landscape of G-quadruplex DNA structural regions in breast cancer. Hansel-Hertsch R, Simeone A, Shea A, Hui WWI, Zyner KG, Marsico G, Rueda OM, Bruna A, Martin A, Zhang X, Adhikari S, Tannahill D, Caldas C, Balasubramanian S.Nat Genet. 2020 Sep;52(9):878-883. doi: 10.1038/s41588-020-0672-8. Epub 2020 Aug 3.PMID: 32747825

  11. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Dev H, Chiang TW, Lescale C, de Krijger I, Martin AG, Pilger D, Coates J, Sczaniecka-Clift M, Wei W, Ostermaier M, Herzog M, Lam J, Shea A, Demir M, Wu Q, Yang F, Fu B, Lai Z, Balmus G, Belotserkovskaya R, Serra V, O'Connor MJ, Bruna A, Beli P, Pellegrini L, Caldas C, Deriano L, Jacobs JJL, Galanty Y, Jackson SP.Nat Cell Biol. 2018 Aug;20(8):954-965. doi: 10.1038/s41556-018-0140-1. Epub 2018 Jul 18.PMID: 30022119

  12. Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts. Callari M, Batra AS, Batra RN, Sammut SJ, Greenwood W, Clifford H, Hercus C, Chin SF, Bruna A, Rueda OM, Caldas C.BMC Genomics. 2018 Jan 5;19(1):19. doi: 10.1186/s12864-017-4414-y.PMID: 29304755

  13. A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren- Douglas A, Barthorpe A, Lightfoot H, O'Connor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C.Cell. 2016 Sep  2;167(1):260-274.e22. doi: 10.1016/j.cell.2016.08.041. Epub 2016 Sep 15.PMID: 27641504

  14. Context-Specific Effects of TGF-β/SMAD3 in Cancer Are Modulated by the Epigenome. Tufegdzic Vidakovic A, Rueda OM, Vervoort SJ, Sati Batra A, Goldgraben MA, Uribe-Lewis S, Greenwood W, Coffer PJ, Bruna A, Caldas C.Cell Rep. 2015 Dec 22;13(11):2480-2490. doi:  0.1016/j.celrep.2015.11.040. Epub 2015 Dec 10.PMID: 26686634 Co-last

Major Funding

As Principal investigator

​

  • Understanding and taking action against the chameleon nature of RMS cells. The Alice’s Arc (2023-2026). £1,125,918.00. Alejandra Bruna and Janet Shipley.

  • Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer. The CCLG Little Princess Trust Project Grant programme (2021-2024). £499,912.00. Alejandra Bruna leader.

  • Decoupling clonal evolution of relapse medulloblastoma. NIHR Great Ormond Street Hospital BRC award -GSM Single Cell Call. £23,478 (2020-2021). Alejandra Bruna and Laura Donovan.

 

As co-investigator

​

  • COMBALK project. Fight Kids Cancer (2021-2024). 499,625€. Alejandra Bruna co-lead.

  • Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven. medulloblastoma: Efficacy, evolution and exploitation. The CCLG Little Princess Trust Project Gran programme (2021-2024). £1,053,351.30. Alejandra Bruna co-leader.

  • CARBEMED: Fight Kids Cancer (2021-2024). 498 799€ . Alejandra Bruna co-lead.

  • •NSTINCT-MB: Strategic implementation of novel combination therapeutics for high-risk Medulloblastoma. Children with Cancer UK. £712,027 (2021-2023). Alejandra Bruna co-leader.

  • EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts. EU H2020 €380,342. 4 years (2018-2022). EuroPDX Consortium, Alejandra Bruna and Carlos Caldas from Cambridge.

bottom of page